UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline

Journal of clinical oncology, 2022-09, Vol.40 (25), p.2957-2995

2022

Volltextzugriff (PDF)

PARP inhibitors in metastatic prostate cancer

Frontiers in oncology, 2023-04, Vol.13, p.1159557

2023

Volltextzugriff (PDF)

Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study

European journal of nuclear medicine and molecular imaging, 2022-05, Vol.49 (6), p.1857-1869

2022

Volltextzugriff (PDF)

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

Journal for immunotherapy of cancer, 2022-03, Vol.10 (3), p.e004198

2022

Volltextzugriff (PDF)

Comparative transfection of DNA into primary and transformed mammalian cells from different lineages

BMC biotechnology, 2010-02, Vol.10 (1), p.9-9, Article 9

2010

Volltextzugriff (PDF)

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort

Frontiers in oncology, 2020-10, Vol.10, p.581189-581189

2020

Volltextzugriff (PDF)

Patterns and predictors of cancer‐specific patient health portal usage among patients with cancer: results from the UWCCC Survivorship Program

Cancer medicine (Malden, MA), 2021-10, Vol.10 (20), p.7373-7382

2021

Volltextzugriff (PDF)

Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma

Molecular oncology, 2021-09, Vol.15 (9), p.2330-2344

2021

Volltextzugriff (PDF)

Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer

Journal for immunotherapy of cancer, 2023-12, Vol.11 (12), p.e008067

2023

Volltextzugriff (PDF)

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023

Journal for immunotherapy of cancer, 2023-02, Vol.11 (2), p.e006551

2023

Volltextzugriff (PDF)

A case of metastatic renal cell carcinoma with concomitant Castleman's disease treated with immunotherapy

Urology case reports, 2021-09, Vol.38, p.101720, Article 101720

2021

Volltextzugriff (PDF)

350 Phase 2 trial of a DNA vaccine with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A377-A377

2021

Volltextzugriff (PDF)

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma

Targeted oncology, 2018-10, Vol.13 (5), p.599-609

2018

Volltextzugriff (PDF)

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network, 2019-12, Vol.17 (12), p.1529-1554

2019

Volltextzugriff (PDF)

506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A538-A538

2021

Volltextzugriff (PDF)

Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) and nivolumab (Nivo) in patients (pts) with nonmetastatic, PSA-recurrent prostate cancer (PCa)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.TPS273-TPS273

2020

Volltextzugriff (PDF)

Clinical significance of D4A in prostate cancer therapy with abiraterone

Cell cycle (Georgetown, Tex.), 2015-10, Vol.14 (20), p.3213-3214

2015

Volltextzugriff (PDF)

A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.TPS239-TPS239

2024

Volltextzugriff (PDF)

A phase Ib/II study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer (mCRPC) and no mutations in DNA damage repair (DDR)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e17036-e17036

2023

Volltextzugriff (PDF)

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Clinical cancer research, 2022-08, Vol.28 (15), p.3248-3255

2022

Volltextzugriff (PDF)

Neutrophil‐to‐eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti‐PD‐1 therapy

Pigment cell and melanoma research, 2023-11, Vol.36 (6), p.501-511

2023

Volltextzugriff (PDF)

A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.TPS5111-TPS5111

2024

Volltextzugriff (PDF)

BIO23-023: Supporting the Capture of Structured Data for Patients With Cancer Using Cancer-Specific Note Templates

Journal of the National Comprehensive Cancer Network, 2023-03, Vol.21 (3.5), p.BIO23-023

2023

Volltextzugriff (PDF)

Getting ready for real‐world use of electronic patient‐reported outcomes (ePROs) for patients with cancer: A National Comprehensive Cancer Network ePRO Workgroup paper

Cancer, 2023-08, Vol.129 (16), p.2441-2449

2023

Volltextzugriff (PDF)

A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3174-TPS3174

2022

Volltextzugriff (PDF)

1 – 25 von 128

Suche als RSS-Feed

Aktive Filter

KollektionSpringer Book Series (Lecture Notes)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(124)
Mit Volltextzugriff
(104)

Publikationsform

Artikel
(127)
Berichte
(1)

Sprache

Englisch
(128)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline

PARP inhibitors in metastatic prostate cancer

Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

Comparative transfection of DNA into primary and transformed mammalian cells from different lineages

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort

Patterns and predictors of cancer‐specific patient health portal usage among patients with cancer: results from the UWCCC Survivorship Program

Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma

Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023

A case of metastatic renal cell carcinoma with concomitant Castleman's disease treated with immunotherapy

350 Phase 2 trial of a DNA vaccine with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors

Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) and nivolumab (Nivo) in patients (pts) with nonmetastatic, PSA-recurrent prostate cancer (PCa)

Clinical significance of D4A in prostate cancer therapy with abiraterone

A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY)

A phase Ib/II study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer (mCRPC) and no mutations in DNA damage repair (DDR)

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Neutrophil‐to‐eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti‐PD‐1 therapy

A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer

BIO23-023: Supporting the Capture of Structured Data for Patients With Cancer Using Cancer-Specific Note Templates

Getting ready for real‐world use of electronic patient‐reported outcomes (ePROs) for patients with cancer: A National Comprehensive Cancer Network ePRO Workgroup paper

A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma

Aktive Filter

Suchergebnisse filtern